Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease
Sofia Bergström(Science for Life Laboratory), Peter Nilsson(Science for Life Laboratory), Julia Remnestål(Science for Life Laboratory), Jennie Olofsson(Science for Life Laboratory), Kaj Blennow(Sahlgrenska University Hospital), Anna Månberg(Science for Life Laboratory), Frederic Brosseron(German Center for Neurodegenerative Diseases), Per Svenningsson(Karolinska Institutet), Raquel Sánchez‐Valle(Biomedical Research Networking Center on Neurodegenerative Diseases), Beatríz Bosch(Biomedical Research Networking Center on Neurodegenerative Diseases), Bengt Nellgård(Sahlgrenska University Hospital), Stéphanie Carvalho(Real Academia Española), Malin Löwenmark(Uppsala University), Kim Kultima(Uppsala University), Michael T. Heneka(University of Massachusetts Chan Medical School), Henrik Zetterberg(University of Wisconsin–Madison), Ioanna Markaki(Beth Israel Deaconess Medical Center), Jamil Yousef(Science for Life Laboratory), Jean‐Christophe Corvol(Centre National de la Recherche Scientifique), Lena Kilander(British Geriatrics Society), Martin Ingelsson(Uppsala University)
Cited by 56
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k